The purpose of this study was to compare perinatal outcomes of pregnancies that undergo "early" (Ͻ17 weeks' gestation) or "late" (Ͼ26 weeks' gestation) fetoscopic laser ablation of placental vascular anastomoses for twin-twin transfusion syndrome (TTTS) with "conventional" cases that were treated at 17-26 weeks' gestation.
T win-twin transfusion syndrome (TTTS) complicates 10-15% of monochorionic/diamniotic twin pregnancies. 1, 2 This syndrome results from unbalanced blood flow through placental vascular anastomoses that results in an hypovolemic, oliguric donor twin with oligoanhydramnios and an hypervolemic, polyuric recipient twin with polyhydramnios. If untreated, mortality rates exceed 90%, and approximately 30% of survivors may show neurodevelopmental impairment. 1, [3] [4] [5] In 2004, a randomized controlled trial demonstrated that fetoscopic laser ablation of placental anastomoses in TTTS resulted in better perinatal outcomes than serial amnioreduction. 6 Only pregnancies at 16-26 weeks' gestation were included in this trial. Part of the rationale for these gestational age limits was that fetoscopic laser ablation at Ͻ16 weeks may be more challenging, because the amnion and chorion may not have yet fused. After 26 weeks' gestation, it was felt that more traditional approaches (such as expectant management, serial amnioreduction, or preterm delivery) were preferred. As is common practice in the first randomized trial that evaluates any new therapy, stringent inclusion and exclusion criteria were set. These trial criteria have been adopted by the Food and Drug Administration (FDA) in the United States, which, under the Humanitarian Device Exemption Program, permits fetoscopic equipment to "be used for the treatment of TTTS for fetuses whose gestational age is between 16 and 26 weeks." 7, 8 In the United States, any fetoscopic procedure outside of these limits can proceed only by special exemption from the FDA.
Extremely premature birth is associated with major long-term handicaps that include cerebral palsy, mental retardation, and/or hearing, visual, and respiratory impairment. 9, 10 Because these fetuses also experience morbidity that is related to TTTS per se (abnormal Doppler results, hydrops, anemia, polycythemia, and renal and cardiac dysfunction 11, 12 ), preterm delivery carries a high risk of significant neonatal morbidity and death, compared with age-matched control subjects, especially at Ͻ29 weeks' gestation. 13 Although TTTS most commonly occurs during the second trimester of pregnancy, it can develop at Ͻ16 and Ͼ26 weeks' gestation. 14 Reports of perinatal outcomes after early and late laser procedures are sparse. 15, 16 The aim of our study was to report on pre-and postnatal characteristics and perinatal outcome of early and late laser procedures and to compare these with procedures that were performed within the more conventional range of 17-26 weeks' gestation.
MATERIALS AND METHODS
We conducted a retrospective chart review of all consecutive monochorionic/ diamniotic twin pregnancies that were complicated by severe TTTS and had been treated with fetoscopic laser ablation of vascular anastomoses at Mount Sinai Hospital, Toronto, Ontario, Canada (a regional/national referral center for fetoscopy) between January 1999 and April 2012. Exclusion criteria were triplets, fetal death at first presentation, and fetal chromosomal or congenital abnormalities. The study was approved by the Research Ethics Board of the hospital (MSH REB #12-0190-C).
TTTS was diagnosed with standard ultrasound criteria 3, 17 that included oligohydramnios (deepest vertical pool, Ͻ2 cm) in the donor and polyhydramnios (deepest vertical pool, Ͼ8 cm at Ͻ20 weeks' gestation or Ͼ10 cm at Ͼ20 weeks' gestation) in the recipient twin. Staging was performed according to Quintero et al 18 (in stage III, the suffix "R" is used when the recipient is affected, and "D" when the donor is affected). Cases were divided into 3 groups based on the timing of the laser procedure: (1) "early," Ͻ17 weeks' gestation, (2) "conventional," 17-26 weeks' gestation; or (3) "late," Ͼ26 weeks' gestation. For the early group, a cutoff of 17 weeks was chosen to allow sufficient power for statistical analysis. Eight cases at Ͻ16 weeks' gestation will be described separately.
Selective laser ablation of placental anastomoses was performed as previously described. 6, 12 Most procedures were performed with local maternal anesthesia (Xylocaine; AstraZeneca, London, UK) with intravenous sedation (remifentanil Ϯ propofol; n ϭ 292 cases); a few cases, during our initial experience, were performed with general (n ϭ 16 cases) or regional (n ϭ 17 cases) anesthesia. A 2-mm 0-degree fetoscope and 3.7-mm (11F) operating sheath (Karl Storz GmbH, Tüttlingen, Germany) and a 600 Nd:YAG laser fiber (Surgical Laser Technologies Inc, Montgomeryville, PA) were introduced through a 12F operating sheath (Cook Medical Inc, Bloomington, IN) that had been inserted directly with the use of a trochar under continuous ultrasound guidance. Thirty-and 70-degree fetoscopes and a curved operating sheath were used, as necessary, for the visualization of anterior placentas. In 1 case of TTTS at 16.1 weeks' gestation with a completely anterior placenta, 900 mL of warmed NaCl 0.9% were first infused into the recipient's sac through a 20-G needle. This amnioinfusion created a safe "window" so that transplacental trochar passage could be avoided.
Intertwin placental vascular anastomoses were identified, and all were ablated selectively along the vascular equator. Amnioinfusion was used as necessary, and, at the end of the procedure, amnioreduction was performed to leave the deepest amniotic fluid pool in the normal range. Prophylactic tocolytics (indomethacin [rectally] and nifedipine [orally] ) and antibiotics (cefazolin [intravenously]) were administered routinely.
After the laser procedures, patients were kept for 1 night in the hospital and discharged the next morning; follow-up evaluation was performed at Mount Sinai, or the patient was referred back to their local regional perinatal center for follow-up evaluation. Details regarding pregnancy and neonatal outcomes were obtained from hospital records, patients, and/or referring physicians.
Demographics, TTTS stage, perioperative characteristics, complications, and maternal and neonatal outcomes were recorded. "Major" maternal complications were defined as (1) intensive care unit admission, (2) pulmonary edema, (3) "mirror" syndrome, or (4) 
RESULTS
In the 13-year study period, 325 cases of severe TTTS were treated with fetoscopic selective laser ablation of the placental anastomoses. Twenty-four cases (7.4%) underwent "early" laser therapy; 283 cases (87.1%) underwent "conventional" laser therapy, and 18 cases (5.5%) underwent "late" laser therapy. Demographics, laser therapy data and complications, TTTS stage, and neonatal outcomes are shown in Table 1 . Maternal characteristics, year of laser procedure, and placental location were similar in all groups.
Early vs conventional laser therapy
TTTS stage, duration of surgery, and need for cerclage were similar in both groups. Although the rate of preterm premature rupture of the membranes (PPROM) at Ͻ32 weeks' gestation was similar between groups, there were more cases of PPROM within 7 days of laser surgery in the early group; there were, however, no differences in the rate of preterm delivery within 7 days, Ͻ28 weeks' gestation, or Ͻ32 weeks' gestation. Laser therapy to delivery interval was longer in early, compared with conventional, cases; the gestational age at delivery was similar in both groups. There were no significant differences in survival at either 7 or 30 days of life for 1 or both fetuses, in neonatal deaths within 7 days of birth, in mode of delivery, or in birthweight between early and conventional cases. There were no differences in maternal complications between the groups (8.3% vs 5%; P ϭ .361). Table 2 summarizes the 8 cases that were treated with laser therapy at Ͻ16 weeks gestation (range, 14.6 -15.6 weeks' gesta- The "early" group (Ͻ17 weeks' gestation; n ϭ 24), the "conventional" group (17-26 weeks' gestation; n ϭ 283), and the "late" group (Ͼ26 weeks' gestation; n ϭ 18). a Data are given as median (range); b Data are given as mean Ϯ SD. 
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Late vs conventional laser therapy
TTTS stage was significantly higher in late cases compared with conventional cases (Table 1) . Indeed, one-third of the recipients were hydropic (stage IV) in the late group, compared with 9.5% in the conventional group (P ϭ .034). There were no differences in either the duration or technical difficulty of laser surgery or in the rate of postoperative complications. Women in the late group delivered later than those in the conventional group; however, the laser therapyto-delivery interval was significantly shorter in late cases compared with conventional cases, although the mean interval in the late group was 6 weeks. Despite late cases presenting at a more advanced stage of TTTS, survival of at least 1 fetus and dual survival were higher in the late group compared with the conventional group. There were no significant differences in birthweight between late and conventional cases. There were no significant maternal complications in the late laser therapy group.
The 18 patients in the late group are detailed in Table 3 . PPROM within 7 days of laser therapy occurred only once. One neonate from the late group died in its first week of life. Two donors (both with stage IV TTTS) died in utero within 24 hours of the laser therapy. In case 4, the prolonged duration of the procedure (142 minutes) was related to closely approximated placental cord insertions and intraamniotic bleeding that necessitated an amnio exchange of 20 L. The recipient died within 24 hours of the procedure, probably of acute severe anemia. A massive grade IV intraventricular hemorrhage was detected in the donor. Labor was induced 6 days after laser therapy with a plan for palliative care, and the neonate died shortly after birth. Finally, in 1 case who underwent surgery at 26.6 weeks gestation for stage IV TTTS, the recipient died unexpectedly 7 weeks after 
COMMENT
In this study, we found that fetoscopic laser therapy for TTTS before either 16 or 17 weeks' gestation and Ͼ26 weeks' gestation was feasible and safe and yielded similar outcomes to cases who were treated between 17-26 weeks. Our data from control group of cases who were treated between 17 and 26 weeks' gestation was similar to previously published studies in terms of gestational age at therapy, perinatal outcome, and complication rates. 6, 19, 20 To our knowledge, this is the first study to evaluate the potential role of fetoscopic laser therapy for severe TTTS at Ͻ16 weeks' gestation. Early TTTS is a rare complication of monochorionic/diamniotic twins; only 8 of 325 cases (2.5%) of our cohort came to our center at Ͻ16 weeks' gestation. Early development of TTTS can pose a diagnostic and therapeutic challenge. The diagnostic criteria may indeed need to be modified slightly 14 : for example, the recipient's bladder may cycle rapidly rather than being persistently distended, and an 8-cm definition for "polyhydramnios" may be too generous at this gestation because fetal blood volume and urine output are less. The volume of amniotic fluid in the recipient's sac may preclude easy trochar insertion; in our experience, previous amnioinfusion by a separate needle, especially with a completely anterior placenta, creates an amniotic fluid "window" that enables safe trochar insertion without traversing the placenta.
Our results demonstrate that laser therapy is a feasible option even at this early stage of pregnancy. Indeed, the duration of fetoscopy, preterm labor rate, and neonatal outcomes in this early laser therapy group were comparable with conventional control subjects. The rate of PPROM within 1 week after laser therapy was increased in the early group; however, this did not translate into an increased rate of premature delivery. This PPROM may be the result of iatrogenic distension of the uterine cavity (amnioinfusion to optimize placental visualization) or the creation of a surgical defect in the membranes and is not the result of an inflammatory or infectious process, which is known to trigger preterm labor. 21 Moreover, recent studies showed that cases of early PPROM 22 and twin pregnancies complicated by PPROM 23 are less likely to be complicated by chorioamnionitis when compared with late PPROM or PPROM in a singleton pregnancy. The rate of PPROM was related inversely to gestational age at laser therapy (Ͻ16 weeks' gestation, 38%; 16-17 weeks' gestation, 19%; Ͼ17 weeks gestation, 6%), which perhaps reflects the degree of chorioamnion fusion with advancing gestation. Despite documented PPROM and occasional transient oligohydramnios, anhydramnios was never observed on ultrasound follow-up evaluation of these cases. Potential strategies to reduce this rate of PPROM might be either the use of a smaller cannula (eg, 10F) or to delay laser procedures until Ͼ17 weeks' gestation; however, the latter option must be weighed carefully against the potential adverse sequelae from progressive TTTS per se. To illustrate this, all but one of our early cases at Ͻ16 weeks' gestation were stage III severe TTTS. Without intervention, early onset severe TTTS is associated with a high perinatal loss rate. 2, 14, 24 Conversely, amnioreduction may compromise later fetoscopic interventions because of intraamniotic bleeding or membrane separation. Some fetal interventions in early pregnancy have been reported to be associated with an increased risk of fetal loss or mechanical fetal anomalies 25, 26 ; however, our results demonstrate the feasibility and safety of laser therapy, even at this early stage of pregnancy. We suggest that, once TTTS is diagnosed in early gestation, all management options, which include selective pregnancy termination, expectant management, amnioreduction, and fetoscopic laser ablation, should be discussed with parents.
When TTTS occurs at Ͼ26 weeks' gestation, management options consist of either serial amnioreduction or preterm delivery, both of which carry a significant risk of neonatal death or major longterm handicap. Indeed, amnioreduction is associated with a 23% rate of neurologic sequelae in survivors, 4, 5, 15, 27, 28 and preterm delivery from 26-28 weeks carries similar neurologic risks in the 70-80% of survivors. 29, 30 Moreover, in our study, in one-third of the TTTS cases who underwent laser therapy at Ͼ26 weeks gestation, the recipient was hydropic (stage IV). At our institution, preterm delivery of a hydropic fetus at Ͻ29 weeks gestation is associated with an almost 100% mortality rate; therefore, in consultation with our neonatal colleagues, we elected to offer laser therapy as an option in these cases. Technical considerations (more turbid amniotic fluid, larger placental vessels, a bigger uterine cavity, and larger fetuses), restrictions by regulatory agencies (eg, FDA), potential maternal risks, and an anecdotally more benign evolution of TTTS after 26 weeks 31 have discouraged many units from offering laser therapy at Ͼ26 weeks' gestation. Late laser therapy, however, may allow time for both fetuses to recover in utero from the cardiac, 11, 12 renal, and other complications of TTTS and should enable the birth of more stable babies at a later gestational age. Even a relatively short period to allow the equilibration of hydropic changes can facilitate resuscitation and improve neonatal outcome. 32 The duration of laser procedure and the complication rates were similar to those cases who were treated from 17-26 weeks' gestation. Moreover, although this did not reach statistical significance, neonatal survival in the late laser therapy group was better than the survival rate in cases who underwent surgery at 17-26 weeks' gestation. There were no major adverse complications related to the laser procedure.
To our knowledge, no studies have been published regarding laser therapy for TTTS at Ͻ16 weeks gestation. Our experience supports the results of 2 previous European studies that reported on fetoscopic laser therapy for TTTS at Ͼ26 weeks' gestation. 15 and mortality rates were worse in the amnioreduction group compared with the laser therapy group. 15 In another study, 28 cases of TTTS who were treated with laser therapy at Ͼ26 weeks' gestation were compared with 324 cases treated between 16-26 weeks' gestation. There were no differences in the duration of surgery, complication rates, gestational age at delivery, or neonatal survival of at least 1 fetus. 16 The main limitations of our study were its retrospective design and the relatively small number of cases that were available for study, especially in the early group. The latter mainly is due to the relative rarity of early and late cases. From a practical perspective, it is unlikely that a randomized controlled trial for early or late TTTS will be conducted because the benefit demonstrated between 16 and 26 weeks' gestation will preclude ethical equipoise. In this situation, a possible source of gathering evidence would be a prospective or retrospective cohort study. We suggest that our study contributes significantly in this field and highlights the need for a large prospective multicenter registry, with detailed neonatal and childhood outcome evaluation.
In our experience, fetoscopic laser therapy at Ͻ17 or Ͼ26 weeks' gestation had similar outcomes compared with laser therapy from 17-26 weeks' gestation. In light of these and other emerging data, we suggest that the current gestational age restrictions for laser therapy of 16-26 weeks should be reevaluated. 
